Nektar Therapeutics Profit Margin

The latest profit margin for NKTR is -287.84% as of June 2026. That compares with -163.17% in the prior-year period — down 76.4% year over year. That is below the Healthcare sector average of 13.39%. Investors often review this figure alongside Nektar Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NKTR's profit margin moved from -163.17% to -287.84% — a 76.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nektar Therapeutics's valuation or profitability profile.

Against Healthcare companies, NKTR currently prints -287.84% for profit margin, while the sector average sits near 13.39%. That is roughly 2250.3% below the sector mean. Large gaps often invite a closer look at Nektar Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Nektar Therapeutics converts resources into returns. At -287.84%, NKTR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -163.17% in the prior-year period — down 76.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NKTR's profit margin (-287.84%), review year-over-year change from -163.17%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.